C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider
4 juli, 09:30
C-RAD, a global leader in surface-guided radiation therapy (SGRT), has signed a premium service agreement with a prominent healthcare provider based on the U.S. East Coast. The multiyear contract, valued at approximately 8 MSEK, builds on a relationship spanning almost a decade and marks an important step in advancing continuity, efficiency, and clinical precision across the provider’s radiation oncology program. The order was signed and recognized as order intake in the second quarter.
The customer’s clinical setup includes multiple Catalyst+ HD and Sentinel 4DCT systems. The new agreement reflects a strategic effort to simplify service management and support long-term system performance and continuity.
“This important partnership demonstrates the provider’s continued confidence in C-RAD’s technology and our team,” says Cecilia de Leeuw, President and CEO of C-RAD. “It underscores the long-term value of our solutions and our ability to deliver consistent, high-quality support. We look forward to deepening our collaboration and helping clinicians advance the standard of care in radiation therapy.”
The key milestone underscores C-RAD’s continued ambition to grow in the U.S. market and supports its broader mission to improve cancer treatment outcomes through innovation and patient-centered technologies. C-RAD remain focused on delivering clinically proven solutions that enable greater precision, workflow efficiency, and safety in radiotherapy.
For further information:
Cecilia de Leeuw, CEO, +46 (0)79 585 6677, investors@c-rad.com
Linda Frölén, CFO, +46 (0)70 303 3253, investors@c-rad.com
About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
Attachments
C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider
Ämnen i artikeln
C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider
4 juli, 09:30
C-RAD, a global leader in surface-guided radiation therapy (SGRT), has signed a premium service agreement with a prominent healthcare provider based on the U.S. East Coast. The multiyear contract, valued at approximately 8 MSEK, builds on a relationship spanning almost a decade and marks an important step in advancing continuity, efficiency, and clinical precision across the provider’s radiation oncology program. The order was signed and recognized as order intake in the second quarter.
The customer’s clinical setup includes multiple Catalyst+ HD and Sentinel 4DCT systems. The new agreement reflects a strategic effort to simplify service management and support long-term system performance and continuity.
“This important partnership demonstrates the provider’s continued confidence in C-RAD’s technology and our team,” says Cecilia de Leeuw, President and CEO of C-RAD. “It underscores the long-term value of our solutions and our ability to deliver consistent, high-quality support. We look forward to deepening our collaboration and helping clinicians advance the standard of care in radiation therapy.”
The key milestone underscores C-RAD’s continued ambition to grow in the U.S. market and supports its broader mission to improve cancer treatment outcomes through innovation and patient-centered technologies. C-RAD remain focused on delivering clinically proven solutions that enable greater precision, workflow efficiency, and safety in radiotherapy.
For further information:
Cecilia de Leeuw, CEO, +46 (0)79 585 6677, investors@c-rad.com
Linda Frölén, CFO, +46 (0)70 303 3253, investors@c-rad.com
About C-RAD
C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort.
C-RAD AB is listed on NASDAQ Stockholm.
For more information on C-RAD, please visit http://www.c-rad.com
Attachments
C-RAD Secures 8 MSEK Service Order with Leading U.S. East Coast Healthcare Provider
Ämnen i artikeln
Börsen idag
-992x558.webp&w=3840&q=75)
Börsen idag
Börsen idag
Mest läst
Börsen idag
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
